Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company pioneering arenavirus-based immunotherapies for cancer and infectious diseases. This page aggregates official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships, providing investors and researchers a centralized resource for tracking the company’s progress.
Users will find timely updates on HOOKIPA’s Vaxwave® and Therat® platforms, which leverage viral vector technology to stimulate durable immune responses. Key content includes trial results for HPV16+ head and neck cancer therapies, hepatitis B/HIV collaboration updates, and financial disclosures. The platform’s stakeholders to monitor developments in immunotherapy approaches designed to overcome traditional treatment limitations.
Bookmark this page for direct access to press releases, SEC filings, and event transcripts. Check regularly for updates on HOOKIPA’s pipeline advancements and industry collaborations that shape its position in the immuno-oncology landscape.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in the virtual 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022, with a corporate presentation scheduled for February 16 at 10:30 AM EST. The presentation will be webcasted, and the replay will be available for 30 days. HOOKIPA focuses on developing novel immunotherapies using its proprietary arenavirus platform to target cancer and other diseases. Its pipeline includes investigational therapeutics for HPV16+ cancers and collaborations aimed at curing HBV and HIV.
HOOKIPA Pharma has initiated the dosing of the first patient with HB-200 and pembrolizumab in a Phase 2 arm of its ongoing Phase 1/2 trial aimed at treating advanced/metastatic HPV16+ head and neck cancer. The FDA has granted Fast Track Designation for HB-200, HB-201, and HB-202/HB-201, recognizing their potential in addressing unmet medical needs. The company's guidance includes further Phase 1 data in mid-2022 and the initiation of a randomized Phase 2 study in 1H 2023. HOOKIPA aims to deliver innovative therapies using its proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will present at the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation, highlighting their innovative immunotherapeutics based on a proprietary arenavirus platform, will be available starting at 7:00 AM EST on January 10. Interested parties can access the webcast via the Investors & Media section of HOOKIPA's website, with a replay accessible for 30 days post-event. HOOKIPA is advancing multiple investigational therapies targeting various cancers and potential cures for HBV and HIV.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in virtual investor meetings and its presentation at The JMP Securities Hematology and Oncology Summit on December 6-7, 2021. The corporate presentation is scheduled for December 7 at 1:20 PM EST, and a webcast will be available on HOOKIPA’s website for 30 days post-event. HOOKIPA is focused on developing immunotherapies using its proprietary arenavirus platform to target various cancers and aims for functional cures of HBV and HIV with Gilead's collaboration.
HOOKIPA Pharma will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. The company’s corporate presentation is scheduled for November 15 at 10:40 AM EST. Interested parties can access the webcast through this link. An archive will be available for 30 days.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces advancements in its oncology pipeline, particularly regarding the HB-201 program. The company is collaborating with Merck & Co. to evaluate HB-201 in combination with pembrolizumab for head and neck cancer patients. Recent interim data for HB-200 shows a 75% disease control rate. However, the financial results reveal a net loss of $20 million for Q3 2021, up from $13.6 million in the same period last year, attributed to increased R&D expenses. HOOK's cash position has also decreased from $143.2 million to $82.7 million.
HOOKIPA Pharma has announced the advancement of HB-201 to Phase 2 clinical trials, targeting HPV16+ head and neck cancers in combination with pembrolizumab. This follows impressive interim Phase 1 data showing a 75% disease control rate and significant tumor shrinkage. In addition, HB-200 demonstrated early anti-tumor activity with 53% of patients experiencing tumor reduction. HOOKIPA is also expanding its oncology pipeline with HB-300 and HB-700 for other cancers, while continuing its promising HB-101 program for kidney transplant patients. Investor insights will be shared in an upcoming call.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its third quarter financial results on November 10, 2021, before market opening. Notably, the company is focusing on developing a new class of immunotherapeutics based on its proprietary arenavirus platform, which activates the immune system against diseases. HOOKIPA is advancing its lead oncology products, HB-201 and HB-202, in clinical trials targeting HPV-related cancers, alongside a CMV vaccine candidate, HB-101. The company also collaborates with Gilead Sciences to research HIV and Hepatitis B treatments.
HOOKIPA Pharma has published a comprehensive review in Frontiers in Oncology, emphasizing the potential of its arenavirus platform as a novel immunotherapy for cancer. The review highlights pre-clinical and clinical data demonstrating effective tumor-specific CD8+ T cell responses following treatment with arenaviral immunotherapies like HB-200, particularly for patients with advanced HPV16+ cancer. HOOKIPA plans to advance HB-200 to Phase 2 trials and explore treatments for other cancers. Initial clinical data show promising efficacy, offering hope for improved cancer treatments.
HOOKIPA Pharma (NASDAQ: HOOK) announces a clinical collaboration with Merck to assess HB-200 with KEYTRUDA as a first-line treatment for advanced head and neck squamous cell carcinoma. This initiative follows promising results from the ongoing Phase 1/2 trial, where HB-201 showed an 18% overall response rate and a median progression-free survival of 3.45 months. Planned Phase 2 trials are set for 2022, indicating HOOKIPA's commitment to advancing its immunotherapeutic pipeline targeting HPV16-positive cancers.
